Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Zevra Therapeutics Inc shares valued at $221,004 were sold by Thompson Rahsaan on Jun 26 ’25. At $9.21 per share, Thompson Rahsaan sold 24,000 shares. The insider’s holdings dropped to 42,666 shares worth approximately $0.49 million following the completion of this transaction.
Also, RAHSAAN THOMPSON purchased 24,000 shares, netting a total of over 223,920 in proceeds.
Before that, Watton Corey Michael had added 300 shares to its account. In a trade valued at $2,352, the Director bought Zevra Therapeutics Inc shares for $7.84 each. Upon closing the transaction, the insider’s holdings increased to 300 shares, worth approximately $20808.0.
As published in their initiating research note from H.C. Wainwright on July 02, 2025, Zevra Therapeutics Inc [ZVRA] has been a Buy and the price target has been revised to $26. As of October 07, 2024, Guggenheim has initiated its “Buy” rating for ZVRA. Earlier on September 24, 2024, Maxim Group resumed its rating. Their recommendation was “a Buy” for ZVRA stock.
Analyzing ZVRA Stock Performance
On last trading session,, Zevra Therapeutics Inc [NASDAQ: ZVRA] rose 0.09% to $11.56. The stock’s lowest price that day was $11.476, but it reached a high of $11.84 in the same session. During the last five days, there has been a surge of approximately 29.16%. Over the course of the year, Zevra Therapeutics Inc shares have jumped approximately 168.52%. Shares of the company reached a 52-week high of $11.84 on 07/09/25 and a 52-week low of $6.19 on 04/09/25.
Support And Resistance Levels for Zevra Therapeutics Inc (ZVRA)
According to the 24-hour chart, there is a support level at 11.41, which, if violated, would cause prices to drop to 11.26. In the upper region, resistance lies at 11.77. The next price resistance is at 11.99. RSI (Relative Strength Index) is 80.47 on the 14-day chart, showing overbought technical sentiment.
Is Zevra Therapeutics Inc subject to short interest?
Stocks of Zevra Therapeutics Inc saw a sharp steep in short interest on 2025-06-13 dropping by -1.3 million shares to 4.71 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 6.01 million shares. A decline of -27.55% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 7.02 of the overall float, the days-to-cover ratio (short ratio) decline to 7.02.
Which companies own the most shares of Zevra Therapeutics Inc (ZVRA)?
In terms of Zevra Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 20 in the next 12 months, up nearly 73.16% from the previous closing price of $11.55. Analysts anticipate Zevra Therapeutics Inc stock to reach 22 by 2025, with the lowest price target being 18. In spite of this, 7 analysts ranked Zevra Therapeutics Inc stock as Buy at the end of 2025. On September 24, 2024, JMP Securities assigned a price target of “a Mkt outperform” to the stock and initiated coverage with a $17.
